


OCTOBER 4, 2018

press_{release}



Smoking cessation: a genetic mutation involved in relapse

Re-exposure to nicotine leads to a higher rate of relapse after cessation and to reduced neuronal activation in the interpeduncular nucleus (IPN) in individuals with a mutation in the $\alpha 5$ nicotinic receptor subunit. © Institut Pasteur

Why is it so difficult to stop smoking? Why do some people relapse months after giving up? Scientists from the Institut Pasteur and the CNRS, in collaboration with Sorbonne University and Inserm, have demonstrated that a genetic mutation already known to be involved in sensitivity to nicotine also plays a role in relapse behavior after cessation in rats. The findings were published in the journal *Current Biology* on October 4, 2018.

Nicotine dependence, a chronic condition with a high rate of relapse, is the leading preventable cause of death in developed countries. Seven million people die from tobacco use every year worldwide.

Nicotine, the main psychoactive compound in tobacco, causes this addiction by binding to the nicotinic receptors in the brain. In so doing it activates the reward circuit and creates a feeling of well-being. An individual's tobacco consumption is therefore closely linked to the sensitivity of these nicotinic receptors, which are composed of five subunits.


In recent years, several large-scale human genetics studies have demonstrated that a mutation in the *CHRNA5* gene that codes for the $\alpha 5$ nicotinic receptor subunit is associated with a significant increase in the risk of nicotine dependence. The mutation is highly present in the general population (approximately 35% of Europeans carry it and up to 50% of the population of the Middle East). These findings led scientists from the Integrative Neurobiology of Cholinergic

Systems Unit (Institut Pasteur/CNRS) to attempt to determine what stage of nicotine dependence is affected by this mutation and to understand its mechanism of action.

The scientists introduced the mutation to a rat by using a recent molecular genetics technique. They then evaluated its effect on various behaviors associated with nicotine dependence and demonstrated that it resulted in greater nicotine consumption in higher doses, as well as an increased rate of relapse to nicotine-seeking behavior after cessation. Interestingly, the research showed that this effect on relapse was associated with reduced neuronal activation in the interpeduncular nucleus, a brain structure with the highest concentration of $\alpha 5$ nicotinic receptor subunits. "This study enabled us to assess the impact of this mutation on various stages of nicotine dependence with a greater degree of accuracy. It provided us with an initial explanation for its mechanism of action, which promotes relapse to nicotine-seeking behavior after smoking cessation," explains Benoit Forget,¹ lead author of the paper.

"The results suggest that a drug capable of increasing the activity of nicotinic receptors containing the $\alpha 5$ subunit could reduce tobacco consumption and lower the risk of relapse after cessation," adds Uwe Maskos, Head of the Integrative Neurobiology of Cholinergic Systems Unit (Institut Pasteur/CNRS) and last author of the paper.

This research was funded by the institutions mentioned above and by the French Foundation for Medical Research (FRM), the European Commission (FP7) and the French National Cancer Institute.



Re-exposure to nicotine leads to a higher rate of relapse after cessation and to reduced neuronal activation in the interpeduncular nucleus (IPN) in individuals with a mutation in the $\alpha 5$ nicotinic receptor subunit (replacement of aspartic acid (D) by asparagine (N)). © Institut Pasteur

¹ Currently a researcher at Pierre & Marie Curie University.

source

A human polymorphism in *CHRNA5* is linked to relapse to nicotine seeking in transgenic rats, *Current Biology*, October 4, 2018

Benoit Forget (1*), Petra Scholze (2), Francina Langa (3), Carole Morel (4), Stephanie Pons (1), Sarah Mondoloni (4), Morgane Besson (1), Romain Durand-de Cuttoli (4), Audrey Hay (4), Ludovic Tricoire (4), Bertrand Lambolez (4), Alexandre Mourot (4), Philippe Faure (4) and Uwe Maskos (1*)

(1) Integrative Neurobiology of Cholinergic Systems Unit, Department of Neuroscience, CNRS UMR 3571, Institut Pasteur, Paris, France.

(2) Department of Pathobiology of the Nervous System, Center for Brain Research, Medical University of Vienna, Spitalgasse 4, 1090 Austria.

(3) Mouse Genetics Engineering Center, CNRS URA 2578, Institut Pasteur, Paris, France

(4) Sorbonne University Association, UPMC Univ Paris 06, INSERM, CNRS, Neuroscience Paris Seine - Institut de Biologie Paris Seine (NPS - IBPS), 75005 Paris, France.

contact

Institut Pasteur Press Office

MYRIAM REBEYROTTE +33 (0)1 45 68 81 01

AURELIE PERTHUISON +33 (0)1 45 68 89 28

presse@pasteur.fr